Duration and association with protection of NANP-repeat-specific and C-terminus-specific anti-circumsporozoite protein IgG responses following RTS,S/AS01E vaccination: an observational ancillary immunological study of a phase 3 clinical trial
The Lancet Infectious Diseases·
- DOI
- 10.1016/s1473-3099(26)00081-2
- PMID
- 42030969
- PMCID
- PMC13261563
- OpenAlex
- W7155102411
- Study type
- Randomised controlled trial
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The findings could inform immunological evaluation of RTS,S/AS01E by identifying antibody durability and maintenance, rather than peak responses alone, as potentially relevant correlates of vaccine efficacy.
Structured evidence summary
Research question
Characterize the durability of antibody responses to circumsporozoite protein regions after RTS,S/AS01E primary and booster vaccination, and assess whether antibody level or maintenance is associated with malaria risk over one year.
Study design
Observational ancillary immunological study of a phase 3 randomized clinical trial, with antibody measurements at five timepoints and analyses using linear regression and Cox models.
Population and setting
The analysis included 1,292 children aged 5–17 months from six African countries who participated in the RTS,S/AS01E phase 3 trial between 2009 and 2011.
Main findings
C-terminus-specific IgG levels declined more slowly than NANP-repeat-specific IgG levels over 17 months after primary vaccination. The abstract states that antibody maintenance was a stronger predictor of vaccine efficacy than peak responses, but the supplied text does not provide the complete statistical results.
Public-health relevance
The findings could inform immunological evaluation of RTS,S/AS01E by identifying antibody durability and maintenance, rather than peak responses alone, as potentially relevant correlates of vaccine efficacy.
Important limitations
The supplied abstract does not report vaccine-group comparisons, effect estimates for clinical malaria, confidence intervals for key associations, or other explicit study limitations. This summary is limited to the supplied single-article abstract and metadata and requires the original paper for decision-grade interpretation.
GIDS interpretation
The article is discoverable as a peer-reviewed 2026 Lancet Infectious Diseases journal article concerning malaria vaccination, vaccine effectiveness, and immunology. This classification provides publication context only and does not establish or confirm any live surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 11 auditable classifier relationships to diseases, places, topics, and study design.